Alphatec Holdings, Inc. (ATEC)
| Market Cap | 1.16B -29.6% |
| Revenue (ttm) | 787.08M +22.5% |
| Net Income | -125.36M |
| EPS | -0.83 |
| Shares Out | 153.79M |
| PE Ratio | n/a |
| Forward PE | 20.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,095,611 |
| Open | 7.98 |
| Previous Close | 7.75 |
| Day's Range | 7.50 - 8.00 |
| 52-Week Range | 6.85 - 23.29 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 18.46 (+145.48%) |
| Earnings Date | May 5, 2026 |
About ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-o... [Read more]
Financial Performance
In 2025, Alphatec Holdings's revenue was $764.16 million, an increase of 24.95% compared to the previous year's $611.56 million. Losses were -$143.36 million, -11.57% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ATEC stock is "Strong Buy." The 12-month stock price target is $18.46, which is an increase of 145.48% from the latest price.
News
Alphatec price target lowered to $24 from $27 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Alphatec (ATEC) to $24 from $27 and keeps an Overweight rating on the shares.
Alphatec price target lowered to $24 from $27 at Barclays
Barclays lowered the firm’s price target on Alphatec (ATEC) to $24 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1
Alphatec price target lowered to $23 from $25 at Canaccord
Canaccord lowered the firm’s price target on Alphatec (ATEC) to $23 from $25 and keeps a Buy rating on the shares. The firm said they posted an uncharacteristic miss in
Alphatec price target lowered to $16 from $24 at JPMorgan
JPMorgan lowered the firm’s price target on Alphatec (ATEC) to $16 from $24 and keeps an Overweight rating on the shares.
Alphatec price target lowered to $11 from $20 at TD Cowen
TD Cowen lowered the firm’s price target on Alphatec (ATEC) to $11 from $20 and keeps a Buy rating on the shares. The firm said sales disappointed, particularly EOS, but
Alphatec price target lowered to $15 from $25 at Lake Street
Lake Street analyst Ben Haynor lowered the firm’s price target on Alphatec (ATEC) to $15 from $25 and keeps a Buy rating on the shares. While “sell reflexes are strong
Alphatec price target lowered to $14 from $25 at Needham
Needham analyst David b lowered the firm’s price target on Alphatec (ATEC) to $14 from $25 and keeps a Buy rating on the shares. The company’s Q1 results missed consensus
Alphatec Holdings, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Alphatec Holdings, Inc. (NASDAQ: ATEC). The investigation focuses on Alphat...
Alphatec Holdings Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 14% year-over-year, driven by strong surgical volume and surgeon adoption, though EOS revenue fell short due to installation delays. Full-year guidance was updated to $882 million revenue and $134 million adjusted EBITDA, with EOS expected to rebound in the second half.
ATEC Reports First Quarter Financial Results
CARLSBAD, Calif--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced f...
ATEC Refinances Existing Debt with Inaugural Bank Facility
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced ...
ATEC to Report First Quarter 2026 Financial Results on May 5, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will r...
Alphatec assumed with an Overweight at Wells Fargo
Wells Fargo assumed coverage of Alphatec (ATEC) with an Overweight rating and $28 price target The firm is maintaining the current rating, price target and estimates.
Alphatec Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Strong growth and profitability were achieved through clinical distinction, surgeon adoption, and share gains amid industry disruption. Enabling technologies like the Valence robot support procedural integration, while disciplined capital deployment and efficient sales force expansion underpin continued confidence in future growth.
Alphatec price target lowered to $20 from $24 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on Alphatec (ATEC) to $20 from $24 and keeps a Buy rating on the shares. The firm updated models across its
Alphatec Holdings Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw 20% and 25% revenue growth, respectively, with strong margin expansion and positive free cash flow. 2026 guidance was raised for both revenue and Adjusted EBITDA, driven by innovation, surgeon adoption, and operational leverage.
ATEC Reports Fourth Quarter and Full-Year 2025 Financial Results
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced ...
Alphatec price target lowered to $20 from $27 at TD Cowen
TD Cowen lowered the firm’s price target on Alphatec (ATEC) to $20 from $27 and keeps a Buy rating on the shares following a transfer of coverage. The firm sees
Alphatec Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Consistent execution and innovation have driven strong growth, with 2025 revenue at $764 million and a target of $890 million for 2026. Investments in informatics and procedural integration, along with international expansion and robust profitability, position the company for continued success.
Alphatec, Theradaptive enter strategic partnership
Alphatec (ATEC) Holdings and Theradaptive announced a definitive strategic partnership agreement. Concurrently, Theradaptive announced the initiation of a Series B investment round designed to acceler...
ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion
ATEC Secures Exclusive U.S. Rights to OsteoAdapt® Platform in Major Strategic Alignment Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology CARLSBAD, Calif. and FREDE...
ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today ...
Alphatec Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference
Lateral spine procedures and robotics are driving strong growth, with significant market expansion potential through technology integration and sales force development. Informatics and automation are set to further differentiate offerings, while disciplined investment supports self-funded growth.